Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive Terminated Phase 1 Trials for Belinostat (DB05015)

IndicationStatusPhase
DBCOND0029923 (Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive)Terminated1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02381548Phase I Trial of AZD1775 and Belinostat in Treating Patients With Relapsed or Refractory Myeloid Malignancies or Untreated Acute Myeloid LeukemiaTreatment